2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational: Molecular and Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1750 Defining the regulatory circuitry of the plasmablastic state identifies p300/CBP as a therapeutic vulnerability in plasmablastic lymphoma

Bomin Ku, PhD, Praveen Tiwari, PhD2, Jessica Duffy, BS3, Genna Mullen, MHS4, Gail Newton, PhD5, Abner Louissaint Jr, MD, PhD6, Christopher Ott, PhD7
1 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
2 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Massachusetts General Hospital, Boston, Massachusetts, United States
5 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
6 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
7 Harvard Medical School, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States

Background: Plasmablastic lymphoma (PBL) is an aggressive B-cell malignancy with poor clinical outcomes and no biologically informed therapies. Treatment strategies have been adapted from diffuse large B-cell lymphoma (DLBCL) and more recently multiple myeloma (MM), yet clinical responses remain limited and short-lived. These limited responses underscore the need to define therapeutic vulnerabilities from PBL’s own biology. Recent collaborative transcriptomic analyses placed PBL in a plasmablastic state sharing features with MM and DLBCL. Whether this transcriptional identity is encoded by a corresponding lineage-specific regulatory landscape and whether this landscape creates therapeutically actionable dependencies remain unknown. Building on our previous demonstration that p300/CBP degradation disrupts enhancer-driven transcriptional programs sustaining MM, we hypothesized that the plasmablastic state in PBL similarly depends on p300/CBP-dependent enhancer circuitry.

Methods: Patient-derived PBL models, including patient-derived xenografts (PDXs) and xenograft-derived cultures (XDCs), were established and molecularly validated through collaborative efforts and used in functional studies. We evaluated p300/CBP degraders alongside domain-selective inhibitors across malignant B-lineage cell lines and PBL models in vitro and in vivo. Chromatin accessibility profiling, transcriptional analysis, pharmacodynamics, and functional genomic analyses were used to define mechanisms underlying therapeutic response.

Results: To determine whether the transcriptional state of PBL is encoded at the chromatin level, we performed ATAC-seq and scored transcription factor motif accessibilities in PBL XDC models (n=2) using chromVAR against MM (n=2) and DLBCL (n=4) cell lines. PBL exhibited low accessibility at B-lineage motifs (SPIB, IKZF1) and high accessibility at plasma cell motifs (IRF4, MAF), while retaining PAX5 accessibility that MM had lost. PBL showed high accessibility at MYC, BACH2 and FOXP1 motifs, which were less accessible in both comparators. Given current treatment practice and the relative regulatory similarity to MM, PBL XDCs were evaluated with anti-MM agents. PBL cells were resistant to dexamethasone and to immunomodulatory drugs while remaining sensitive to bortezomib and selinexor. These findings demonstrate that shared transcriptional features do not confer shared therapeutic vulnerabilities, emphasizing the need to define them from PBL’s own biology.

Guided by our previous demonstration that p300/CBP degradation dismantles enhancer-dependent transcriptional programs in MM, we evaluated whether this dependency extends to PBL. Across a panel of 44 human malignant B-lineage cell lines, the p300/CBP degrader dCBP-30 demonstrated greater antiproliferative activity than either lysine acetyltransferase domain (A-485) or bromodomain (GNE-781) inhibition [median IC50 12.60 nM vs 795.43 nM and >10,000 nM], establishing targeted protein degradation as a more potent pharmacologic strategy. This activity extended to patient-derived PBL models, where dCBP-30 induced efficient degradation of p300/CBP and greater antiproliferative activity than domain-selective inhibitors, including the bromodomain inhibitor inobrodib, which is currently in phase II clinical evaluation. Oral dCBP-30 significantly inhibited tumor growth in a PBL xenograft model at 15 mg/kg and produced minor regression at 30 mg/kg, with immunohistochemistry confirming marked loss of p300 and CBP in treated tumors.

Integrated epigenome profiling and targeted CRISPR perturbation support the existence of a distinct regulatory landscape that is selectively perturbed following p300/CBP degradation, and a central role for p300/CBP-dependent enhancer programs in maintaining PBL cell fitness. Genome-scale CRISPR screening is in progress to integrate with multiomic analyses and to further refine the regulatory circuitry sustaining the plasmablastic state and identify additional lineage-specific therapeutic vulnerabilities.

Conclusions: PBL is sustained by a regulatory landscape distinct from the diseases it resembles, resulting in unique therapeutic vulnerabilities. These findings identify p300/CBP-dependent enhancer circuitry as a defining feature of the plasmablastic malignant state and establish targeted protein degradation as both a mechanistic tool for interrogating lineage-specific regulatory programs and a promising therapeutic strategy for PBL.

Bomin Ku, PhD: No relevant conflicts of interest to declare.